5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach. Sixteen patients were treated, 12 with metastatic and 4 with locoregional disease. Responses were seen in 6 of 16 patients (all partial responses), for an overall response rate of 37.5%. The sites of response include liver (3), lung (1), bone (1), and lymph nodes (1). Median duration of response was 7 months. These results with FAM in adenocarcinoma of the esophagus suggest activity similar to that seen in gastric carcinoma. The second-generation chemotherapy combinations effective in gastric carcinoma merit evaluation in this tumor to see if the remission rates could be further improved.
Khansur
T
T
Division of Oncology, University of Mississippi School of Medicine, Jackson.
Allred
C
C
Tavassoli
M
M
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D004943:Esophagogastric Junction; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D012074:Remission Induction; D016019:Survival Analysis
D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil